Actor Shreyas Talpade suffers heart attack, undergoes angioplasty
Mumbai (PTI): Actor Shreyas Talpade suffered a heart attack and is recuperating in a hospital here after undergoing an angioplasty, an official of the medical facility said on Friday.
The 47-year-old reportedly complained of uneasiness and collapsed at his residence on Thursday. He was rushed to the Bellevue Hospital in Andheri by his family.
"He was brought to the hospital late last evening and an angioplasty was performed last night. He is fine. He is in the ICU," the official told PTI.
As per media reports, Talpade had returned home Thursday from the shoot of his upcoming movie "Welcome to the Jungle".
A family member said the actor was recovering well and urged the media to maintain privacy.
"He is doing well. He is doing much better. We would request you to give us privacy," the family member told PTI.
The actor who has starred in both Hindi and Marathi cinema is best known for his performance in films such as "Iqbal", "Dor", "Om Shanti Om" and the "Golmaal" franchise.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
New study reveals adverse events in some covaxin recipients
New Delhi: A recent study conducted by Sankha Shubhra Chakrabarti and his team at Banaras Hindu University has shed light on adverse events observed in participants who received Covaxin, Bharat Biotech's COVID-19 vaccine.
The study involved 1,024 individuals, comprising 635 adolescents and 291 adults, who were followed up for one year after receiving Covaxin.
Nearly a third of the participants reported adverse events of special interest (AESI) during the observation period. These included viral upper respiratory tract infections, new-onset skin and subcutaneous disorders, general disorders, nervous system disorders, menstrual abnormalities in females, ocular abnormalities, and hypothyroidism.
The study identified several risk factors associated with AESI. Female adolescents and individuals with a history of allergies were found to be at higher risk. Additionally, participants with pre-vaccination COVID-19, comorbidities, and post-vaccination typhoid were also identified as having increased risk.
A significant number of AESIs persisted even at the 1-year follow-up. Female individuals, adolescents with pre-vaccination COVID-19, those with comorbidities, and those with post-vaccination typhoid had higher odds of persistent AESIs.
Among serious adverse events, stroke and Guillain-Barre Syndrome were identified in a small percentage of participants.
The study highlights the importance of extended surveillance of COVID-19 vaccinated individuals to understand the course and outcomes of late-onset adverse events. Focused monitoring for persistent AESIs is recommended, especially for individuals with certain risk factors.
The findings suggest that the patterns of adverse events observed with Covaxin differ from those reported with other COVID-19 vaccines. Understanding these patterns is crucial for effective post-vaccination monitoring and management of potential risks.
